Funded Projects › H2020
PIBD-SETQuality · Paediatric Inflammatory Bowel Diseases Network for Safety, Efficacy, Treatment and Quality improvement of care
The incidence of paediatric onset Inflammatory Bowel Diseases (PIBD) has risen dramatically in recent decades. Compared to adult forms, PIBD reflects a more severe disease, more often requiring aggressive treatment with immunomodulators, and thereby exposing children to a life-long risk of serious disease and treatment-related adverse events, such as infections and malignancies. Therefore, there is an urgent need to develop strategies which balance, on an individual basis, therapeutic effectiveness with risks of treatment.The overall goal of this proposal is to develop and validate a treatment algorithm for PIBD based on high or low risk predictors for early complicated or relapsing disease. This will improve effectiveness, while reducing treatment related risks and life-long complications due to uncontrolled disease progression.To attain this goal 3 specific aims are proposed under the umbrella of an international network, the ""PIBD-net"": 1) Development of an accessible and feasible risk-stratified treatment algorithm for new onset paediatric IBD on an existing inception cohort and validation in an independent cohort2) Generation of a prospective large longterm real world inception cohort in a registry designed to analyze effectiveness and safety signals and correlate them to individual risk factors 3) Design and performance of a risk algorithm-based prospective large-scale multicenter randomized clinical trial (RCT) (stratification into high or low risk groups based on specific aim#1) in order to provide optimal personalized therapy : low risk azathioprine vx. methotrexate, high risk : methotrexate vx. adalimumabThis project will translate into the first risk-stratified PIBD treatment algorithms allowing optimization of medical therapy while minimizing treatment-related risk (personalized medicine).""
Consortium · 14 organisations
UNIVERSITE PARIS CITE
FR · €580,000
GREATER GLASGOW HEALTH BOARD
UK · €431,459
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
DE · €120,895
DEUTSCHE MORBUS CROHN/COLITIS ULCEROSA VEREINIGUNG BUNDESVERBAND FUR CHRONISCH ENTZUNDLICHE ERKRANKUNGENDES VERDAUUNGSTRAKTES (DCCV) EV
DE · €33,750
VRIJE UNIVERSITEIT BRUSSEL
BE · €259,720
AIMES GRID SERVICES COMMUNITY INTEREST COMPANY
UK · €51,375
VIB VZW
BE · €150,000
SHAARE ZEDEK MEDICAL CENTER
IL · €427,339
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL · €682,980
QUEEN MARY UNIVERSITY OF LONDON
UK · €331,750
THE FOUNDATION FOR MEDICAL RESEARCH AND DEVELOPMENT OF INFRASTRUCTURES AND HEALTHCARE SERVICES BY THE E WOLSFON MEDICAL CENTER
IL · €176,612
AIMES MANAGEMENT SERVICES LIMITED
UK · €17,375
UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
IT · €192,862
PEDIATRIC INFLAMATORY BOWEL DISEASES NETWORK PIBD-NET
FR · €2,539,882
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.